UK-based specialty pharmaceutical company EUSA Pharma has received European approval for the immunotherapy dinutuximab beta, as a treatment for high-risk neuroblastoma patients over the age of one.
The rare cancer, which predominantly affects children under five, is the second most common solid tumor in childhood. Every year in Europe, around 1,200 children are diagnosed.
Dinutuximab beta, an antibody that has been investigated in clinical trials involving over 1,000 patients, has orphan drug designation in the USA and EU.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze